Physician profile

Steven E Morton

Internal Medicine · Corbin, KY

NPI 1932104767

$5,908.58

in general payments reported to CMS, 2019-2025

39 companies · $107 in 2025

The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,549.02
Education$21.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $649.76 2019-2023 Verquvo, Belsomra, Steglatro
Pfizer INC. $587.21 2019-2025
Astellas Pharma US INC $547.51 2019-2023 Myrbetriq, Veozah
Lilly USA, LLC $493.01 2019-2023 Mounjaro, Trulicity, Jardiance
Astrazeneca Pharmaceuticals Lp $400.14 2019-2023 Farxiga, Breztri
Novo Nordisk INC $391.83 2019-2023 Ozempic, Rybelsus
Novartis Pharmaceuticals Corporation $340.85 2019-2023
Abbott Laboratories $323.45 2021-2023 Freestyle Libre 3, Freestyle Libre 2
Abbvie INC. $315.13 2019-2025
Janssen Pharmaceuticals, INC $209.99 2020-2023 Spravato
Amarin Pharma, INC. $190.31 2019-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $174.52 2019-2023 Xifaxan
Amgen INC. $158.90 2019-2025 Otezla, Repatha, Tezspire
Seqirus USA INC $154.15 2024 Fluad, Flucelvax
Alexion Pharmaceuticals, INC. $118.57 2019-2022
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $115.90 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $96.74 2021
Evoke Pharma, INC. $75.54 2022-2023 Gimoti
E.R. Squibb & Sons, L.L.C. $73.77 2019-2022
Otsuka America Pharmaceutical, INC. $59.55 2021-2023 Rexulti
Sumitomo Pharma America, INC. $56.72 2023 Gemtesa
Lundbeck LLC $36.45 2023 Rexulti
Sunovion Pharmaceuticals INC. $36.07 2019-2022
Biohaven Pharmaceuticals, INC. $30.79 2021
Acadia Pharmaceuticals INC $29.23 2021
Neurocrine Biosciences, INC. $27.47 2022-2023 Ingrezza
Jazz Pharmaceuticals INC. $21.75 2021
Supernus Pharmaceuticals, INC. $18.99 2019
Verona Pharma, INC. $18.42 2025 Ohtuvayre
Kowa Pharmaceuticals America, INC. $17.61 2022
Ultragenyx Pharmaceutical INC. $17.57 2024 Crysvita
Dexcom, INC. $17.32 2021
Eisai INC. $17.25 2021
Allergan, INC. $16.67 2020
Glaxosmithkline, LLC. $15.12 2023 Shingrix
Genentech USA, INC. $13.99 2020
Sanofi-Aventis U.S. LLC $13.91 2023
Collegium Pharmaceutical, INC. $13.68 2021
Livanova USA, INC. $12.74 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven E Morton

$5,908.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Merck Sharp & Dohme LLC
Context
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/86917/steven-e-morton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.